Skip to search formSkip to main contentSkip to account menu

c-Met Inhibitor MSC2156119J

Known as: MSC2156119J 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The current standard treatment option for advanced hepatocellular carcinoma (HCC) is sorafenib, but its clinical benefit is… 
2015
2015
2591 Background: Tumor c-Met overexpression is associated with tumor aggression and poor prognosis, making it a target for… 
2015
2015
Objectives: To evaluate the dose/exposure/target inhibition/tumor growth relationship of MSC2156119J, an orally administered… 
2014
2014
The mesenchymal-epithelial transition factor (c-Met) is a receptor tyrosine kinase with hepatocyte growth factor (HGF) as its… 
2014
2014
2521^ Background: MSC2156119J, a selective c-Met inhibitor, suppresses tumor growth in preclinical models. Methods: Primary… 
2014
2014
TPS4151 Background: Patients (pts) with HCC have a poor prognosis. Effective treatments are limited, particularly in Asia, which… 
2014
2014
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Overexpression of the c-Met oncoprotein can… 
2014
2014
ABSTRACT Aim: c-Met overexpression is associated with poor clinical prognosis. This dose-escalation study (3 + 3 design… 
2014
2014
ABSTRACT Background: Sorafenib remains the only approved systemic first-line medical treatment for advanced hepatocellular…